Trial to Assess the Ocular Safety of Vorapaxar (SCH 530348) in Participants With Atherosclerosis (Study P05183)
Status:
Completed
Trial end date:
2010-10-01
Target enrollment:
Participant gender:
Summary
This study is designed to evaluate the long-term ocular safety of SCH 530348 (vorapaxar) in
participants with established atherosclerotic disease who are enrolled into the TRA 2°P -
TIMI 50 Study (P04737) (NCT00526474).
Phase:
Phase 3
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.
Collaborators:
Duke Clinical Research Institute The TIMI (Thrombolysis in Myocardial Infarction) Study Group